Precision Medicine Online

Abpro to Study Bispecific T-cell Engager ABP-102 in HER2-Positive Cancers

The firm expects to begin the Phase I trial in HER2-positive breast and gastric cancers in the first half of 2026.
Ophthalmology Times

FDA extends Aldeyra's reproxalap PDUFA after requesting additional clinical study report

The US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for Aldeyra’s New Drug Application (NDA) for reproxalap for the treatment of dry ...

Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Version of CIPRO® HC (ciprofloxacin 0.2% HCl and hydrocortisone 1% otic suspension), wit…

Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated pharmaceutical company, announced today that the U.S. Food and ...
The Manila Times

Recludix Pharma Announces FDA Clearance of Investigational New Drug Application for REX-8756, an Oral STAT6 Inhibitor, to Enter into the Clinic

REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in preclinical models of asthma, acute lung inflammation and ...
VCCircle

Senores Pharma snaps up Gujarat-based drugmaker to enter UK, Canada markets

Senores Pharmaceuticals Ltd said it has acquired a Gujarat-based pharmaceutical company along with five of its drug ...
BioSpace

Big Pharma Pushes FDA To Decouple Inspections From Drug Approval Applications

Representatives of companies including AbbVie, Eli Lilly, Johnson & Johnson and Merck have voiced concerns about the FDA’s ...